Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay. The company was founded in 2012 and is headquartered in Nanjing, China.
Metrics to compare | 9887 | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship Relationship9887PeersSector | |
---|---|---|---|---|
P/E Ratio | −45.7x | −13.2x | −0.5x | |
PEG Ratio | - | 0.28 | 0.00 | |
Price/Book | 68.8x | 7.0x | 2.6x | |
Price / LTM Sales | - | 19.1x | 3.3x | |
Upside (Analyst Target) | - | 3.8% | 42.8% | |
Fair Value Upside | Unlock | −13.1% | 6.5% | Unlock |